---
layout: post
title: "Phenylketonuria Market to Reach New Heights by 2034, Driven by Innovative Therapies and Rising Diagnosis Rates | DelveInsight"
date: 2026-02-18T22:31:00+00:00
source: PR Newswire Releases
source_url: https://www.prnewswire.com/news-releases/phenylketonuria-market-to-reach-new-heights-by-2034-driven-by-innovative-therapies-and-rising-diagnosis-rates--delveinsight-302691158.html
significance: 7.00
---

<p>With several potential therapies, including Sepiapterin (PTC Therapeutics), NGGT002 (NGGT), JNT-517 (Jnana Therapeutics), Pegvaliase (BioMarin), and others under investigation, the phenylketonuria treatment landscape is expected to undergo substantial transformation between 2025 and 2034....</p>

**Source:** [PR Newswire Releases](https://www.prnewswire.com/news-releases/phenylketonuria-market-to-reach-new-heights-by-2034-driven-by-innovative-therapies-and-rising-diagnosis-rates--delveinsight-302691158.html)

**Published:** 2026-02-18 22:31:00 +0000

**Significance Score:** 7.00

[View original](https://www.prnewswire.com/news-releases/phenylketonuria-market-to-reach-new-heights-by-2034-driven-by-innovative-therapies-and-rising-diagnosis-rates--delveinsight-302691158.html)
